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Abstract
Background: Seizures in individuals affected by tuberous sclerosis complex (TSC) commonly develop in the first
year of life, are often preceded by a progressive deterioration of the electroencephalogram (EEG), and likely
influence developmental outcome. Although early diagnosis of TSC has offered a tremendous opportunity to
monitor affected patients before seizure onset, reports of the neurological manifestations of TSC in infants before
seizure onset are still scarce. Here we describe early EEG activity, clinical and genetic data and developmental
assessment in a group of TSC infants, with the aim of identifying possible prognostic factors for
neurodevelopmental outcome.
Methods: We report on six infants diagnosed with TSC pre- or perinatally, who underwent serial Video-EEG
recordings during the first two years of life. EEGs were classified based on distribution and intensity of interictal
epileptiform discharges, and Vigabatrin was introduced in case of ictal discharges. Psychomotor development,
cognitive functioning and behavioral problems were assessed through standardized scales. Molecular testing
included analysis for point mutations and deletions/duplications in TSC1 and TSC2.
Results: EEG abnormalities appeared at a mean age of 4 months. Four of the six patients developed seizures. EEG
abnormalities preceded the onset of clinical seizures in all of them. The two individuals with good seizure control
showed normal development, while the other two exhibited psychomotor delays. The patients who did not
develop seizures had normal development. A pathogenic variant in the TSC2 gene was detected in all patients but
one. The one without a mutation identified did not develop seizures and showed normal neurodevelopment. Of
note, the two patients presenting with the worst outcome (that is, poor seizure control and intellectual/behavioral
disability) both carried pathogenic variants in the GAP domain of TSC2.
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Conclusion: Our report supports the importance of EEG monitoring before seizure onset in patients with TSC, and
the correlation between prompt seizure control and positive neurodevelopmental outcome, regardless of seizure
type. Our results also indicate a possible role of the genetic background in influencing the outcome.
Keywords: Tuberous sclerosis complex, TSC1, TSC2, Seizure, Infancy, Electroencephalography, Neurodevelopmental
outcome
Introduction
Tuberous Sclerosis Complex (TSC) is a multisystem
neurocutaneous disorder caused by heterozygous patho-
genic variants in TSC1 (Chr. 9q34.13) or TSC2 (Chr.
16p13.3) [1]. It is characterized by hamartomas affecting
the brain, skin, eye, heart, lung, and kidney. The typical
Central Nervous System (CNS) lesions are present in
more than 90% of the patients and consist of cortical tu-
bers, white matter radial migration lines, subependymal
nodules (SENs), and subependymal giant cell astrocyto-
mas (SEGAs) [1]. Up to 85% of the affected individuals
have a diagnosis of epilepsy, and seizure onset in the
first year of life is very common (67%) [2]. TSC may
therefore be considered a genetic developmental and
epileptic encephalopathy [3], as both genetic factors and
epileptic activity contribute to the phenotype. Early on-
set epilepsy usually presents with focal seizures or in-
fantile spasms, but all seizure types have been clinically
described [4, 5].
There is a strong association between intellectual dis-
ability (ID) and epilepsy [6], and it is recognized that early
seizure onset may negatively contribute to worsening the
final developmental outcome. On the other hand, the in-
fluence of subclinical seizures has yet to be clarified [3, 5].
Recent studies have shown that many infants develop
a progressive deterioration of the EEG during the first
months of life, before the onset of seizures [3, 7, 8]. Fur-
thermore, clinically silent seizures can be present in pa-
tients with TSC, and are difficult to detect unless an
ictal EEG is available [9, 10].
Close EEG monitoring (i.e. every 4–6 weeks) during
the first months of life allows for early detection of elec-
troencephalographic seizures and for prompt treatment
to minimize the deleterious impact of early-onset sei-
zures [11, 12].
Nowadays, a diagnosis of TSC may be suspected pre-
natally if cardiac rhabdomyomas are detected on fetal
ultrasound, and is subsequently confirmed soon after
birth by the presence of skin findings [13], brain find-
ings, or molecular testing. Thus, early diagnosis has
allowed clinicians to follow children with TSC before
the development of neurological signs. To the best of
our knowledge, there are only few reports of the neuro-
logical manifestations of TSC in infants before seizure
onset. In this study, we describe early EEG activity,
clinical and genetic data, and developmental outcome in
order to identify prognostic factors that could lead to a
better management of these children.
Material and methods
We performed a retrospective study of children referred
to our TSC clinic, which now comprises over 200 indi-
viduals. We selected those who had been suspected to
have TSC prenatally, perinatally, or in the first 6 months
of life and had been followed at our clinic on a regular
basis since 2013. A definite diagnosis of TSC was estab-
lished after birth according to the 2012 revised criteria
[1].
Our standard clinical practice consists of serial Video-
EEG recordings every 4–8 weeks during the first two
years of life. In addition to video-EEG monitoring, par-
ents are educated on how to recognize and video record
subtle seizures and spasms, in case seizures develop in
between two recordings.
If seizures occur, antiepileptic treatment with Vigaba-
trin is introduced, starting from 50mg/Kg/day up to
100–150mg/Kg/day, according to the current clinical
recommendations [14]. Patients with normal EEG re-
cordings are followed up without any antiepileptic
medications.
Scalp-EEGs with synchronized video are recorded ac-
cording to the International 10–20 system, modified for
newborns using our Institution’s clinical EEG software
(Micromed, System plus). All EEG recordings include at
least the following channels (Fp2-C4, C4-O2, Fp2-T4,
T4-O2, Fp1-C3, C3-O1, Fp1-T3, T3-O1, T4-C4, C4-Cz,
Cz-C3, C3-T3), along with electrocardiography (ECG),
deltoid muscles, and breathing recordings. In infants,
EEGs are recorded applying the International 10–20 sys-
tem of electrode placement directly or by cable telemetry
with more than 16 channels and at least 3 polygraphic
channels (ECG and deltoid muscles).
Prolonged recordings (at least 90 min) during wakeful-
ness and sleep were obtained for all patients.
We reviewed and analyzed each EEG for:
Background activity appropriate for age, and normal
sleep pattern (i.e. presence of sleep spindles, tracè
alternante for the newborn);
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Presence of epileptiform discharges (focal, multifocal,
generalized);
Presence of hypsarrhythmia;
Presence of electroclinical seizures.
We analyzed EEG abnormalities applying the classifi-
cation proposed by Domanska-Pakiela et al. [7], which is
based on interictal epileptiform discharges’ (IEA) distri-
bution and their intensity. EEGs were analyzed by two
epileptologists (AM and AV), who were blinded to the
patients’ management. Details of the methods used for
analyzing EEGs are presented in Table 1. All the patients
underwent brain MRI studies performed with a 1.5 Tesla
magnet, including fluid-attenuated inversion recovery
(FLAIR) sequences to detect the presence of typical cere-
bral lesions (cortical tubers, subependymal nodules,
white matter migration lines, and SEGA).
Psychomotor development (total Developmental Quo-
tient: DQ) or cognitive level (total Intelligence Quotient:
IQ) was assessed through standardized scales (Griffiths’
Scales of Infant Development, GMDS-ER, Wechsler Pre-
school and Primary Scales of Intelligence, WPPSI). Be-
havioral problems were investigated through prolonged
clinical observations, caregivers’ reports, and standard-
ized tests in children.
Molecular genetic testing for TSC1/TSC2 was available
for all the patients, and included analysis for point muta-
tions and deletions/duplications in both genes. All vari-
ants identified were submitted to a publicly available
database, whenever not already present (http://chro-
mium.lovd.nl/LOVD2/TSC/home.php).
Results
The study cohort consisted of 6 children (4 boys and 2
girls). The diagnostic criteria that were present in each
patient at time of enrolment are reported in Table 2.
The diagnosis was suspected following the detection of
cardiac rhabdomyomas (3 prenatally, 2 perinatally, and 1
at age 6 months) in all the patients. Subsequent skin
examination, neuroimaging, eye examination and ab-
dominal ultrasonography showed the presence of hypo-
melanotic macules, retinal hamartomas, cortical
dysplasia (including tubers and cerebral white matter ra-
dial migration lines) and subependymal nodules as the
second major diagnostic criterion. No renal angiomyoli-
pomas have been detected in these young patients yet,
whereas in three individuals renal cysts were present at
the time of evaluation (Patients n. 3, 5 and 6).
Genetic testing documented pathogenic variants in
TSC2 in all but one patient. In one individual no muta-
tions in TSC1/TSC2 were identified.
Age at first evaluation ranged from 4 weeks to 6
months, depending on different referrals, with a follow-
up of 2–4 years.
Patient 1
Patient 1 was born at 37 gestational weeks by caesarean
section for breech presentation, after an uneventful preg-
nancy. Multiple cardiac rhabdomyomas were detected in
the neonatal period. Cardiac arrhythmias were recorded
on 24-h EKG Holter monitoring, and treatment with
Beta-blockers and Flecainide acetate was started.
The first EEG was performed at age 4 months and was
normal. EEGs performed every 8 weeks showed the pres-
ence of normal background activity with multifocal
spikes and sharp waves in sleep, involving the occipital
left region (since age 8 months), the right fronto-
temporal region (since age 12months), or the left
fronto-temporal region (18 months). We classified Pa-
tient 1 as C1 [Fig. 1]. Interictal discharges disappeared
by age 24 months. She never experienced epileptic
seizures.
Neurological examination and psychomotor develop-
ment were normal at two years of age (DQ 98, Griffiths
Scales). Genetic testing showed a pathogenic variant in
exon 24 of TSC2: c.2771_2772del (p.Phe924*).
Patient 2
Patient 2 was born at 32 weeks by caesarean section,
after a pregnancy complicated by maternal hypertension
and diabetes mellitus type 1. Apgar score was 5–9 and
weight was 2360 g. Delivery was complicated by peri-
natal respiratory distress and pneumothorax requiring
continuous positive airways pressure (CPAP) ventilation.
Multiple cardiac tumors were detected at 6 months of
age.
The first EEG was performed at age 6 months, and
was normal. Follow up EEGs were done every 8 weeks,
and remained normal until age 2 years.
At age 10 months he presented with an isolated seizure
associated with fever. The seizure was characterized by
Table 1 EEG’s abnormalities classification
Distribution of IEA Intensity of IEA
A One region (one focus) 1 Irregular spikes or sharp waves
B One hemisphere (> 1 focus) 2 Irregular spike and wave complexes
C Multifocal (at least 2 foci, each in a different hemisphere) 3 Continuous spike and waves complexes
D Generalized 4 Hypsarrhythmia
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staring and clonic jerks involving the upper limbs,
followed by spontaneous recovery in about 2 min.
Neurological examination and neuropsychological de-
velopment at 34 months of age were normal (DQ 91,
Griffiths Scales).
Molecular analysis for TSC1 and TSC2 point muta-
tions (through next generation sequencing) and dele-
tions/duplications was negative.
Patient 3
Patient 3 was born at 37 weeks of gestation by vaginal
delivery. Multiple cardiac tumors had been detected on
prenatal ultrasonography at 32 weeks of gestation, and
were confirmed by fetal MRI. The first EEGs were per-
formed during the neonatal period and at 3 months of
age at a different institution, and were normal.
Seizures occurred at age 4months and the patient was
therefore referred to our TSC clinic. They were charac-
terized by series of infantile spasms, with focal motor
signs and asymmetric involvement of the upper limbs
(more on the left side) documented on parents’ video re-
cordings. EEG was performed, and showed interictal dis-
charges characterized by frequent multifocal spikes and
spike-and-waves complexes during wakefulness and
sleep involving mainly the right centro-temporal region.
We did not record hypsarrhythmia. We classified this
patient’s EEG features as C3. The patient was started on
Vigabatrin at 75 mg/Kg/day, and seizures have been con-
trolled since the first day of treatment. He has been seiz-
ure free to the time of last assessment.
Follow-up EEG performed at age 6 months (2 months
after starting Vigabatrin) was normal, and remained nor-
mal through age 17–24months.
At two years of age, neurological examination and
neuropsychological assessment were normal (DQ 89,
Griffiths Scales), with mild language delay.
Genetic tests identified a large deletion involving
exons 17–22 of TSC2.
Patient 4
Patient 4 was born at 40 weeks by vaginal delivery after
an uneventful pregnancy. Multiple cardiac rhabdomyo-
mas had been detected prenatally. The first EEG was
performed at age 8 weeks and was normal. Follow up
EEG performed 8 weeks later showed focal spikes and
spike waves complexes during sleep over the right cen-
tral region. The option of preventive antiepileptic treat-
ment with Vigabatrin was proposed, but the family
decided to wait and delayed the appointment for EEG
recordings.
Three months later, at age 7 months, the parents re-
ported a series of infantile spasms on awakening.
EEG was performed, and showed frequent interictal
discharges, characterized by multifocal spike and wave
discharges with diffusion during sleep. We never re-
corded the presence of hypsarrhythmia. This patient was
classified as D3 [Fig. 2].
She was treated with Vigabatrin (100 mg/Kg/day), with
good seizure control since the first week of treatment.
Follow-up EEGs showed progressive decrease of epi-
leptic discharges at age 8, 10 and 12 months, and were
Fig. 1 Patient 1 at age 12 months. EEG recording shows normal background activity with multifocal spikes and sharp waves during sleep,
involving the fronto-temporal regions of both hemispheres. The child did not experienced seizures. Interictal discharges disappeared by
age 24months
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completely normal at serial recordings after the first year
of age.
Neuropsychological development at age 28months
was normal (DQ 104, Griffiths Scales). Neurological
evaluation was normal.
A pathogenic variant was identified in exon 30 of
TSC2: c.3626 T > C (p.Leu1209Pro), inherited from her
affected mother.
Patient 5
The child was born by vaginal delivery after an unevent-
ful pregnancy. He presented with cardiac arrhythmias
during the neonatal period, and subsequent echocardiog-
raphy showed multiple cardiac rhabdomyomas. The first
EEG was performed at age 4 weeks and was abnormal,
showing focal interictal discharges over the right fronto-
temporal region. The first EEG was performed at our
clinic at 4 months of age, and showed an increase in epi-
leptic discharges with frequent multifocal spike-and-
waves complexes during sleep. While the parents were
deciding whether or not to start treatment with Vigaba-
trin, the family noticed a series of infantile spasms four
days after the first EEG recording. The patient was ad-
mitted to the hospital, and seizures were recorded at
video EEG monitoring. They were characterized by
series of spasms with ictal EEG correlates of pseudo
periodic high voltage generalized slow waves. Interictal
EEG showed multifocal spike and spike-and-waves dis-
charges, with bilateral activation and diffusion during
sleep. This patient was classified as D3. Treatment with
Vigabatrin (titrated to 150 mg/Kg/day) was started, with
control of seizures from the 10th day of treatment.
At 8 months of age he experienced seizures associated
with fever; valproic acid was added, with good seizure
control.
At age 20months the patient started to present poly-
morphic seizures, characterized by prolonged focal
clonic seizures involving the left arm during febrile ill-
nesses, with or without bilateral tonic-clonic evolution.
Relapsing epileptic spasms coexisting with focal subtle
seizures were documented from age 20 months. He was
treated with several AEDs with unsatisfactory results.
Epilepsy is still drug-resistant at the time of last
assessment.
Follow up EEG performed at age 6, 8 and 12months
showed persistent multifocal discharges.
At age 4 years a SEGA of 13 × 10mm located near the
left foramen of Monro was detected on brain MRI,
which was stable at neuroradiological follow-up.
At the time of last assessment, the patient’s psycho-
motor development was delayed and moderate cognitive
impairment was diagnosed (IQ 48, WPPSI at age 4
years). Autism spectrum disorder (ASD) was also diag-
nosed (ADOS evaluation).
Genetic testing showed a pathogenic variant in exon
34 of TSC2: c.4544_4547delACAA (p.Asn1515Serfs*60).
Patient 6
The patient was born at term after an uneventful preg-
nancy. Multiple cardiac tumors had been detected pre-
natally. Brain MRI showed bilateral cortical and
Fig. 2 Patient 4 at age 7 months. EEG shows frequent interictal discharges, characterized by diffused spike and wave discharges. At this time, she
experienced epileptic spasms and she was treated with Vigabatrin. Seizures were promptly controlled. At follow-up EEGs were completely normal
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cerebellar tubers, and a large malformation of cortical
development involving the fronto-temporal bilateral
regions.
The first EEG performed at age 8 weeks was normal.
At age 4 months, he started to present focal seizures
characterized by staring, head and eye deviation, with
sparing of the left arm.
Focal seizures arising from the right frontal region
were recorded at Video-EEG. Interictal EEG was charac-
terized by focal spike and spike-and-waves discharges on
the right fronto-temporal region.
At 7 months of age the patient started to present in-
fantile spasms associated with subtle focal seizures. Sleep
EEG was characterized by diffuse slow activity with spor-
adic spike and wave discharges predominantly on the
right fronto-temporal region, without hypsarrhythmia.
The patient was classified as B2 [Fig. 3].
Treatment with Vigabatrin initially introduced for
focal seizures, was titrated up to 120 mg/Kg/day. Due to
drug-resistant seizures, Levetiracetam, Topiramate and
Carbamazepine in different combinations were intro-
duced with unsatisfactory results.
Follow-up EEGs confirmed the presence of persisting
interictal discharges that were predominant over the
right fronto-temporal regions.
Patient 6’s psychomotor development was delayed
based on neuropsychological testing performed at age
24months (DQ 69, Griffiths Scales), with predominant
speech delay.
Genetic testing showed a de novo pathogenic variant
in exon 35 of TSC2: c.4570dup (p.Ser1524Serfs*5).
The course of EEG activity and epilepsy for each pa-
tient is reported in Fig. 4.
Discussion
Most Authors recognize a link between early seizure on-
set and poor long-term neurological and behavioural
outcome [15]. This has stimulated several investigators
to develop strategies to prevent seizure onset [12]. As-
suming that interictal epileptiform abnormalities (IEA)
in children with TSC can be considered a marker of the
dynamics of the epileptogenic process [7], multicenter
prospective randomized double-blind clinical trials are
currently ongoing, aiming at verifying the impact of the
treatment of preclinical vs. clinical seizures (EPISTOP
project in Europe and PREVENT trial in the United
States [NCT02849457]). However, data about early EEG
monitoring in TSC patients are limited in the literature
[7, 15].
While waiting for the results of these seminal studies,
in clinical practice we are faced with newborns referred
for TSC due to the improvement of ultrasound tech-
niques during pregnancy. Nowadays TSC is increasingly
more frequently diagnosed in the prenatal period or in
early infancy, thus offering the possibility of monitoring
children before the onset of seizures and/or neurodeve-
lopmental delay [16].
According to the clinical recommendations for man-
agement of epilepsy in TSC [14], treatment should be
initiated in infants and children within 24months of age
if ictal discharges occur, with or without clinical
manifestations.
Fig. 3 Patient 6 at age 7 months. Sleep EEG was characterized by diffuse slow activity with sporadic spike and wave discharges predominantly on
the right fronto-temporal region. He showed both focal seizures and epileptic spasms
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Since 2013, we have had the opportunity to follow 6
infants with TSC starting from the first months of life.
All of them received video-EEG recordings every 4–8
weeks. The aim of the present study was to describe the
electro-clinical and neurodevelopmental outcome in 6
children with early diagnosis of TSC.
Although limited by the small number of individuals
included in this study and the relatively short follow-up,
neither age at EEG abnormalities appearance nor EEG
characteristics at onset were sufficient for determining
long-term prognosis. Indeed, one of the patients de-
scribed herein showed EEG abnormalities for months
and never developed seizures (Patient 1). Her neurode-
velopment is normal. On the other hand, disappearance
of EEG abnormalities was related to good prognosis for
both epilepsy and cognitive outcome.
Mean age at EEG abnormalities appearance was 4
months, in line with that reported in larger cohorts by
Jozwiack et al. [12].
According to the EEG classification proposed by
Domanska-Pakiela et al. [7], irregular and continuous
spike-and-waves complexes, either localized on one
hemisphere or multifocal, were more frequently seen
also in our group of patients. Clear hypsarrhythmia was
not identified on the EEGs even though four infants
showed IS.
The lack of EEG deterioration could be explained by
the close EEG monitoring leading to early treatment of
IS, which did not allow the progression of epileptiform
activity [7]. This finding should be considered a typical
feature in TSC, and clinicians should not wait to start
antiepileptic treatment [8].
In addition, seizure type - either focal seizures or IS -
did not correlate with epilepsy or intellectual prognosis
in our sample.
The major contribution to neurodevelopment seems
not only linked to seizure onset but rather to the oppor-
tunity of their prompt control, as seen in patients 3 and
4 from our cohort. This finding is in line with the recent
work by Capal et al. [17], demonstrating that timing of
complete seizure control, in particular at age 12months,
is predictive of global development and ASD behaviors
in the long-term.
Moreover, our data further confirm that the refractori-
ness of seizures is associated with cognitive disability, as
seen in Patients 5 and 6 and reported by Humphrey
et al. [18], who demonstrated that IQ decline is associ-
ated with duration of infantile spasms in infants with
TSC.
Nevertheless, it is known that seizures are not the only
determinant of cognitive status in TSC. Genetic factors,
i.e. pathogenic variants in TSC2 rather than TSC1 [19],
have been recognized as a significant risk factor for earl-
ier and more severe epilepsy, as well as for a higher rate
of cognitive impairment, with due exceptions [20, 21].
Specifically, TSC2 pathogenic variants have been asso-
ciated with a significantly higher occurrence of IS and
other epilepsy types. However, certain missense muta-
tions located in the central region of TSC2 (exons 23–
33) have been reported to be associated with a reduced
incidence of IS [22]. In fact, we are aware of patients
Fig. 4 Course of EEG activity and epilepsy for each patient: the green bar represents normal EEG, while the red one the occurrence of EEG
abnormalities. ND = Normal Development, ID = Intellectual Disability, ASD = Autism Spectrum Disorder, IS = Infantile Spasms, FS = Focal Seizures.
The star indicates drug responsive seizures
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with central missense mutations presenting with IS. Of
note, Patient 4 in our cohort exhibited a missense vari-
ant in exon 30 of TSC2 and presented with infantile
spasms, but had normal development. This suggests that,
although infantile spasms can be seen in patients with
central missense mutations (yet, significantly less fre-
quently than in patients with different TSC2 pathogenic
variants), developmental outcome could be favorable.
Our small group of children with TSC was genetically
homogenous. A pathogenic variant in TSC2 was de-
tected in all but one: the latter did not develop seizures
and has normal neurodevelopment. On the other hand,
the two patients with the worst outcome, in terms of
seizure control and intellectual/behavioral disability,
both carried pathogenic variants in exons 34 and 35 of
TSC2.
As hypothesized by Kothare and colleagues [23],
changes in the TSC2 GAP domain may lead to a more
pronounced mTOR hyperactivation and a more severe
phenotype. We therefore hypothesize that pathogenic
variants in exons 34–35 of TSC2 (GAP domain) are re-
sponsible for the worst outcome in the two infants in
our sample, but this finding should be confirmed in big-
ger cohorts.
Taken together, these observations led us to infer that
genotype itself could influence the outcome in patients
with TSC, at times independent from epilepsy onset,
seizure type, and seizure control. However, further stud-
ies on larger numbers of patients are warranted to verify
this hypothesis.
In addition to the influence of seizures and genetics
on the outcome, neuropathological findings, such as a
higher tuber/brain proportion [6] or the number of ra-
dial migration lines [24] have been demonstrated to con-
tribute to cognitive and behavioural phenotype. All our
patients showed multiple cortical tubers and subependy-
mal nodules, as well as white matter radial migration
lines on brain MRI, so that this finding was difficult to
correlate to the patients’ outcome. The fact that intellec-
tual dysfunction has been reported in patients without
epilepsy [5] or with no apparent brain lesions [25], as
well as in animal models of TSC [26], suggests that the
neurological and behavioral problems in TSC may some-
how emerge independently from seizure onset, and be
presumably related to underlying altered CNS develop-
ment and neuronal connectivity.
Nevertheless, epileptic activity and brain structural al-
terations may also interact with each other, and seizures
may result as a trigger for predisposed structures or pro-
vide additional insult worsening intellectual disability, as
recently suggested [17].
Both early onset seizures and CNS abnormalities in
TSC are genetically determined through a cascade of
events involving early mTOR overactivation.
This consideration may open the way to the possibility
of early treatment with mTOR inhibitors for TSC-
related neuropsychiatric disorders. However, in experi-
mental models, animals that were treated prenatally with
mTOR inhibitors exhibited long-term cognitive sequelae
[27]. On the other hand, administration of mTOR inhib-
itors in the early postnatal period resulted in preventing
seizure onset or in making seizures cease if given after
epilepsy onset [28].
Only limited human data on early postnatal use of
mTOR inhibitors are available, suggesting this treatment
is scarcely effective in preventing seizure onset [29].
Vigabatrin is recognized to be the most effective treat-
ment for IS and focal seizures starting in infants with
TSC. In addition to inhibiting GABA-transaminase and
increasing the synaptic concentration of GABA in the
brain, it also plays a role in inhibiting mTOR overactiva-
tion, and may have an impact on glutamatergic trans-
mission, which is essential for neurodevelopment [30].
Inflammatory mechanisms involving specific cytokines
and chemokines are abnormally activated in mouse
models of TSC, and inhibition of these mechanisms was
associated with a decrease in seizures and improved sur-
vival in these mice [31]. Starting from this proof-of-
concept, other modulating factors should be further con-
sidered in children with TSC, and anti-inflammatory
treatments may represent potential therapy for this gen-
etic epilepsy.
Conclusion
Our report supports the importance of EEG monitoring
before seizure onset in TSC patients, and the correlation
between seizure control and positive neurodevelopmen-
tal outcome. Although we could not find specific predic-
tors, mainly because of the small number of patients
analysed, we hypothesize a role of the genetic back-
ground in influencing the outcome. Hopefully, ongoing
studies on large populations of children with TSC will
delineate the key players of neurodevelopmental out-
come in the near future.
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